Compile Data Set for Download or QSAR
Report error Found 39 Enz. Inhib. hit(s) with all data for entry = 50032036
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323635(6-(4-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataKi:  96nMAssay Description:Competitive inhibition of MK2 ATP-binding siteMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323635(6-(4-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataKi:  310nMAssay Description:Uncompetitive inhibition of MK2 ATP-binding siteMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323635(6-(4-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataKi:  320nMAssay Description:Mixed inhibition of MK2 ATP-binding siteMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323634(6-(4-bromophenyl)-N-(4-(4-methylpiperazin-1-yl)phe...)
Affinity DataIC50: 400nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323635(6-(4-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataKi:  480nMAssay Description:Noncompetitive inhibition of MK2 ATP-binding siteMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323635(6-(4-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataIC50: 600nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323645(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(4-(methylt...)
Affinity DataIC50: 700nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323636(6-(4-fluorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataIC50: 700nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323646(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-p-tolylquin...)
Affinity DataIC50: 800nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323647(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-m-tolylquin...)
Affinity DataIC50: 1.40E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323644(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(4-(trifluo...)
Affinity DataIC50: 1.40E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323640(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(3-(trifluo...)
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323643(4-(4-(4-(4-methylpiperazin-1-yl)phenylamino)quinol...)
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323641(6-(3-chlorophenyl)-N-(4-(4-methylpiperazin-1-yl)ph...)
Affinity DataIC50: 2.60E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323630(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-phenylquino...)
Affinity DataIC50: 5.20E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323642(6-(3-methoxyphenyl)-N-(4-(4-methylpiperazin-1-yl)p...)
Affinity DataIC50: 8.00E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323638(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(3-nitrophe...)
Affinity DataIC50: 9.00E+3nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323618(4-(6-(4-chlorophenyl)quinolin-4-ylamino)benzoic ac...)
Affinity DataIC50: 1.20E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323639(6-(3-aminophenyl)-N-(4-(4-methylpiperazin-1-yl)phe...)
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323623((4-(6-(4-chlorophenyl)quinolin-4-ylamino)phenyl)(4...)
Affinity DataIC50: 1.50E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323615(2-(4-(6-phenylquinolin-4-ylamino)phenyl)ethanol | ...)
Affinity DataIC50: 2.20E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323619(4-(6-(4-chlorophenyl)quinolin-4-ylamino)phenol | C...)
Affinity DataIC50: 2.30E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323620(6-(4-chlorophenyl)-N-(4-morpholinophenyl)quinolin-...)
Affinity DataIC50: 2.40E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323625(4-(6-p-tolylquinolin-4-ylamino)phenol | CHEMBL1208...)
Affinity DataIC50: 2.50E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323631(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(thiophen-3...)
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323622(4-(6-(4-chlorophenyl)quinolin-4-ylamino)benzonitri...)
Affinity DataIC50: 2.70E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323626(4-(6-p-tolylquinolin-4-ylamino)benzonitrile | CHEM...)
Affinity DataIC50: 2.70E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323621(2-(4-(6-(4-chlorophenyl)quinolin-4-ylamino)phenyl)...)
Affinity DataIC50: 2.90E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323624(4-chloro-2-(6-p-tolylquinolin-4-ylamino)phenol | C...)
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323627(N-(2,3-dimethylphenyl)-6-p-tolylquinolin-4-amine |...)
Affinity DataIC50: 3.50E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323616(N-(4-ethylphenyl)-6-phenylquinolin-4-amine | CHEMB...)
Affinity DataIC50: 4.10E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323628(4-chloro-2-(6-phenylquinolin-4-ylamino)phenol | CH...)
Affinity DataIC50: 4.30E+4nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323617(N-(4-morpholinophenyl)-6-phenylquinolin-4-amine | ...)
Affinity DataIC50: 1.20E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323629(N-(4-chloro-2-fluorophenyl)-6-(4-chlorophenyl)quin...)
Affinity DataIC50: 1.21E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50196110(N-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-ami...)
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323614(N,6-diphenylquinolin-4-amine | CHEMBL1209750)
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323633(N-(4-(4-methylpiperazin-1-yl)phenyl)-6-(thiophen-2...)
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323632(6-bromo-N-(4-(4-methylpiperazin-1-yl)phenyl)quinol...)
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Astrazeneca R & D Lund

Curated by ChEMBL
LigandPNGBDBM50323637(4-(4-(4-(4-methylpiperazin-1-yl)phenylamino)quinol...)
Affinity DataIC50: 2.00E+5nMAssay Description:Inhibition of MK2 assessed as inhibition of [33P]ATP incorporation in to substrate after 30 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2011
Entry Details Article
PubMed